Merck Keynote 671 Study and Overall Survival in Lung Cancer

Episode 76

Biotech Hangout

CHAPTER

Merck Keynote 671 Study and Overall Survival in Lung Cancer

Discussion on the Merck Keynote 671 study, focusing on resectable lung cancer at stage 2, 3A, or 3B. The study reveals that giving Keytruda before surgical resection has shown an overall survival advantage, marking a significant development in neo-adjuvant studies with a PD-1 in lung cancer.

00:00

Transcript

Play full episode

Remember Everything You Learn from Podcasts

Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.